Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 1, 2007, Pages 225-233

  Newell, Kelly A ^a,b   Zavitsanou, Katerina ^a,b,c   Jew, Stephen Kum ^d   Huang, Xu Feng ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b Neuroscience Institute of Schizophrenia and Allied Disorders   (Australia)

^c AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

3H muscimol; 3H pirenzepine; Human brain; Posterior cingulate cortex; Receptor density; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; BENZATROPINE; CLOZAPINE; HALOPERIDOL; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; MUSCIMOL; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PIRENZEPINE; QUINUCLIDINYL BENZILATE; RECEPTOR SUBTYPE; RISPERIDONE; SERTRALINE; TEMAZEPAM; THIORIDAZINE; TRITIUM;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; IMAGING SYSTEM; LIMBIC SYSTEM; MALE; MEDICAL INSTRUMENTATION; MENTAL DISEASE; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PSYCHOPHARMACOLOGY; QUANTITATIVE ANALYSIS; RAT; RECEPTOR DENSITY; SCHIZOPHRENIA; SUICIDE;

ADULT; AGED; AUTORADIOGRAPHY; FEMALE; GABA AGONISTS; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; MUSCIMOL; PIRENZEPINE; RECEPTORS, GABA; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA;

EID: 33845683345     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.07.004     Document Type: Article

References (53)

1. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney Jr. W.E., et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52 (1995) 258-266 [see comment]
2. American Psychiatric Association, A.P. Diagnostic and statistical manual of mental disorders: DSM-IV, 4 (1994), American Psychiatric Association, Washington, DC
3. Ball S., Busatto G.F., David A.S., Jones S.H., Hemsley D.R., Pilowsky L.S., et al. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. Biol Psychiatry 43 (1998) 107-117
4. Benes F.M., Vincent S.L., Alsterberg G., Bird E.D., and SanGiovanni J.P. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12 (1992) 924-929
5. Benes F.M., Vincent S.L., Marie A., and Khan Y. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75 (1996) 1021-1031
6. Benes F.M., Wickramasinghe R., Vincent S.L., Khan Y., and Todtenkopf M. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res 755 (1997) 121-129
7. Billard W., Binch III H., Crosby G., and McQuade R.D. Identification of the primary muscarinic autoreceptor subtype in rat striatum as m2 through a correlation of in vivo microdialysis and in vitro receptor binding data. J Pharmacol Exp Ther 273 (1995) 273-279
8. Bird E.D., Spokes E.G., Barnes J., MacKay A.V., Iversen L.L., and Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet 2 (1977) 1157-1158
9. Bird E.D., Spokes E.G., and Iversen L.L. Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain 102 (1979) 347-360
10. Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., David A.S., Lucey J.V., et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry 154 (1997) 56-63 [see comment][erratum appears in Am J Psychiatry 1997 May; 154 (5):722]
11. 3H]-5-HT-moduline binding sites in rodent brain and their relationship to 5-HT1B receptors. Proc Natl Acad Sci USA 94 (1997) 9899-9904
12. Crespo-Facorro B., Wiser A.K., Andreasen N.C., O'Leary D.S., Watkins G.L., Boles Ponto L.L., et al. Neural basis of novel and well-learned recognition memory in schizophrenia: a positron emission tomography study. Hum Brain Mapp 12 (2001) 219-231
13. 3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 64 (1999) 1761-1771
14. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48 (2000) 381-388
15. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158 (2001) 918-925
16. Dean B., Crook J.M., Opeskin K., Hill C., Keks N., and Copolov D.L. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1 (1996) 54-58 [see comment]
17. Dean B., Gray L., Keriakous D., and Scarr E. A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus and Related Systems vol. 2 (2004) 287-295
18. Deng C., and Huang X.F. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 81 (2005) 883-890
19. Farnbach-Pralong D., Bradbury R., Copolov D., and Dean B. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors. Eur J Pharmacol 349 (1998) R7-R8
20. 3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse 14 (1993) 283-296
21. 3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 40 (1987) 259-266
22. Haznedar M.M., Buchsbaum M.S., Hazlett E.A., Shihabuddin L., New A., and Siever L.J. Cingulate gyrus volume and metabolism in the schizophrenia spectrum. Schizophr Res 71 (2004) 249-262
23. Hyde T.M., and Crook J.M. Cholinergic systems and schizophrenia: primary pathology or epiphenomena?. J Chem Neuroanat 22 (2001) 53-63
24. Katerina Z., Andrew K., Filomena M., and Xu-Feng H. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29 (2004) 619-625
25. Kim S.H., Price M.T., Olney J.W., and Farber N.B. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. Mol Psychiatry 4 (1999) 344-352
26. Langlois X., te Riele P., Wintmolders C., Leysen J.E., and Jurzak M. Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists. J Pharmacol Exp Ther 299 (2001) 712-717
27. Li Q., Clark S., Lewis D.V., and Wilson W.A. NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity. J Neurosci 22 (2002) 3070-3080
28. Mackay A.V., Iversen L.L., Rossor M., Spokes E., Bird E., Arregui A., et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39 (1982) 991-997
29. Mai J.K., Assheuer J., and Paxinos G. Atlas of the Human Brain (1997), Academic Press, London
30. Mash D.C., Flynn D.D., and Potter L.T. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228 (1985) 1115-1117
31. Mitelman S.A., Shihabuddin L., Brickman A.M., Hazlett E.A., and Buchsbaum M.S. Volume of the cingulate and outcome in schizophrenia. Schizophr Res 72 2,3 (2004) 91-108
32. Moore H., Fadel J., Sarter M., and Bruno J.P. Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience 88 (1999) 811-822
33. Newell K.A., Zavitsanou K., and Huang X.F. Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. NeuroReport 16 (2005) 1363-1367
34. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52 (1995) 998-1007 [see comment]
35. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., and Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 254 (1991) 1515-1518
36. Perry T.L., Kish S.J., Buchanan J., and Hansen S. Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet 1 (1979) 237-239
37. Piggott M., Owens J., O'Brien J., Paling S., Wyper D., Fenwick J., et al. Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain. J Chem Neuroanat 24 (2002) 211-223
38. Raedler T.J., Knable M.B., Jones D.W., Lafargue T., Urbina R.A., Egan M.F., et al. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 23 (2000) 56-68
39. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Egan M.F., and Weinberger D.R. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 28 (2003) 1531-1537
40. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Gorey J.G., Lee K.S., et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 160 (2003) 118-127
41. Reynolds G.P., Czudek C., and Andrews H.B. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatry 27 (1990) 1038-1044
42. Sanz B., Exposito I., and Mora F. M1 acetylcholine receptor stimulation increases the extracellular concentrations of glutamate and GABA in the medial prefrontal cortex of the rat. Neurochem Res 22 (1997) 281-286
43. Sarter M., Bruno J.P., and Turchi J. Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Ann N Y Acad Sci 877 (1999) 368-382
44. Simpson M.D., Slater P., Deakin J.F., Royston M.C., and Skan W.J. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 107 (1989) 211-215
45. Steiger J.L., and Russek S.J. GABAA receptors: building the bridge between subunit mRNAs, their promoters, and cognate transcription factors. Pharmacol Ther 101 (2004) 259-281 [erratum appears in Pharmacol Ther. 2004 Sep; 103 (3):261]
46. Tendolkar I., Weis S., Guddat O., Fernandez G., Brockhaus-Dumke A., Specht K., et al. Evidence for a dysfunctional retrosplenial cortex in patients with schizophrenia: a functional magnetic resonance imaging study with a semantic-perceptual contrast. Neurosci Lett 369 (2004) 4-8
47. van Kammen D.P., Sternberg E.M., Hare-James T.A., Ballenger J.C., Marder S.R., Post R.M., et al. Schizophrenia: low spinal fluid GABA levels?. Brain Res Bull 5 (1980) 731-735
48. Vilaro M.T., Wiederhold K.H., Palacios J.M., and Mengod G. Muscarinic M2 receptor mRNA expression and receptor binding in cholinergic and non-cholinergic cells in the rat brain: a correlative study using in situ hybridization histochemistry and receptor autoradiography. Neuroscience 47 (1992) 367-393
49. Vogt B.A., Finch D.M., and Olson C.R. Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex 2 (1992) 435-443
50. Volpicelli L.A., and Levey A.I. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 145 (2004) 59-66
51. Zavitsanou K., Katsifis A., Yu Y., and Huang X. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 65 (2005) 397-403
52. Zilles K., Werner L., Qu M., Schleicher A., and Gross G. Quantitative autoradiography of 11 different transmitter binding sites in the basal forebrain region of the rat-evidence of heterogeneity in distribution patterns. Neuroscience 42 (1991) 473-481
53. Zink M., Schmitt A., May B., Muller B., Demirakca T., Braus D.F., et al. Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr Res 66 (2004) 151-157